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Against the Stream Series
Development and change often arise by challenging the status quo. In the arena of mental health and in the
practice of psychiatry, the need to question and the importance of critiquing are paramount. Hence, we have
decided to introduce a new series of articles to be published in this and forthcoming issues of the BJPsych
Bulletin. Each piece will tackle controversial issues of relevance to psychiatrists and mental health profes-
sionals. The position taken by the authors will be contrary to received wisdom on the subjects, hence
the title of the series – Against the stream. The articles will not be accompanied by an opposing view
but, of course, readers are most welcome to contribute their views via eLetters and, indeed, we hope
very much that lively discussion will ensue.
Philip Graham and Peter Tyrer
Against the stream: Antidepressants are not
antidepressants – an alternative approach to
drug action and implications for the use
of antidepressants
Joanna Moncrieﬀ1
BJPsych Bulletin (2018) 42, 42–44, doi:10.1192/bjb.2017.11
1University College London, UK
Correspondence to Joanna Moncrieﬀ
(j.moncrieﬀ@ucl.ac.uk)
First received 06 Jul 2017, accepted
04 Aug 2017
© The Author 2018. This is an Open
Access article, distributed under the
terms of the Creative Commons
Attribution licence (http://
creativecommons.org/licenses/by/
4.0/), which permits unrestricted re-
use, distribution, and reproduction in
any medium, provided the original work
is properly cited.
Summary Although antidepressants are regarded as eﬀective and speciﬁc
treatments, they are barely superior to placebo in randomised trials, and diﬀerences
are unlikely to be clinically relevant. The conventional disease-centred understanding
of drug action regards antidepressants as targeting an underlying brain process, but
an alternative ‘drug-centred’ view suggests they are psychoactive substances that
modify normal mental states and behaviour. These alterations, such as numbing of
emotions, may reduce feelings of depression, and also create ampliﬁed placebo
eﬀects in randomised trials. Patients should be informed that there is no evidence
that antidepressants work by correcting a chemical imbalance, that antidepressants
have mind-altering eﬀects, and that evidence suggests they produce no noticeable
beneﬁt compared with placebo.
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Antidepressants are by far the most commonly prescribed
class of drug for mental disorders, and their use continues
to rise.1 Huge marketing campaigns have persuaded the gen-
eral public that depression is a ‘chemical imbalance’ that anti-
depressants can help reverse. Professional organisations claim
that antidepressants are an eﬀective and speciﬁc treatment
for depression, and that they are considerably more eﬀective
than placebo. The Royal College of Psychiatrists’ current
information leaﬂet suggests that 50–65% of people who are
given an antidepressant will show ‘much improvement’ within
3 months, compared with only 25–30% on placebo.2
The evidence base
Overall, randomised controlled trials show that depression rat-
ings decrease slightly more with antidepressants than placebo.
Studies are inconsistent, however, and diﬀerences are small,
especially when unpublished trials are included. Reviews of
the literature on tricyclic and older antidepressants concluded
that ‘in well-designed studies, the diﬀerences between antide-
pressants and placebo are not impressive’.3 Meta-analyses of
trials of selective serotonin reuptake inhibitors (SSRIs) and
other modern antidepressants that include unpublished trials
have found mean diﬀerences between antidepressants and pla-
cebo ranging from 1.80 to 2.55 points on the widely used
Hamilton Rating Scale for Depression.4–6
The clinical signiﬁcance of such small diﬀerences is
doubtful. The Hamilton scale has a total score of 54 points.
A recent analysis comparing scores on the Hamilton scale
with scores on the observer-rated Clinical Global Impression
(CGI) scale suggests that a diﬀerence of three points on the
Hamilton scale is equivalent to a rating of ‘no diﬀerence’ on
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the CGI scale, while a diﬀerence of eight points is required to
obtain CGI scale ratings of ‘mild improvement’.7,8
Antidepressant/placebo diﬀerences therefore appear to fall
well below levels required to make a noticeable diﬀerence in
someone’s condition.
Antidepressant eﬀects and severity
It is often suggested that antidepressants are more eﬀective,
or perhaps only eﬀective, in severe depression, and that this
can explain their poor performance relative to placebo in
trials with mixed populations. Some meta-analyses have
found a gradient between the size of the antidepressant/pla-
cebo diﬀerence and the severity of initial depression across
trials,5,9 although diﬀerences in people with the most severe
depression still fall well below those equating to ‘mild
improvement’ on the CGI. Other meta-analyses have not
identiﬁed a severity gradient.10,11
Older evidence suggests that antidepressants are not
particularly helpful for inpatients with depression. A
Medical Research Council trial, for example, found little dif-
ference between imipramine, phenelzine and placebo.12
Trials of antidepressants for the treatment of depression in
people with bipolar disorder have also found no diﬀerences
between antidepressants and placebo.13
Antidepressant eﬀects and the drug-centred
model of drug action
The accepted view of drug action in psychiatry is that psychi-
atric drugs work by targeting a putative underlying brain
abnormality. I have called this the ‘disease-centred’ model
of drug action. An alternative explanation is the ‘drug-
centred’ model, which suggests that psychiatric drugs inﬂu-
ence symptoms of mental disorder and distress through
their psychoactive eﬀects. ‘Psychoactive’ drugs, sometimes
referred to as ‘mind-altering drugs’, include recreational
drugs, drugs prescribed for mental health problems and
some other medical drugs (e.g. steroids, anticholinergics).
They modify normal thoughts, emotions and behaviours in
characteristic ways. According to the drug-centred model
of drug action, for example, antipsychotics reduce the symp-
toms of psychosis through their ability to produce a state of
mental slowing and emotional restriction, a state they pro-
duce in animals and humans, regardless of the presence of
psychiatric or behavioural problems. Anxiolytics reduce
symptoms of anxiety through their well-known sedative
and relaxant eﬀects, which occur independently of any psy-
chiatric disorder.
Elsewhere, I have outlined the lack of evidence for the
disease-centred view of drug action for any class of psychi-
atric medication.14 The serotonin and noradrenaline theories
of depression, which appear to explain the action of antide-
pressants in a disease-centred manner, are not supported by
evidence or expert opinion.15,16 Moreover, numerous rando-
mised trials have shown that drugs that are not considered as
antidepressants, and have actions on other neurotransmitter
systems, including benzodiazepines, opiates, stimulants and
antipsychotics, are as eﬀective as recognised antidepressants
in people with depression.15
The drug-centred model suggests that the mental and
physical alterations produced by antidepressants account
for the diﬀerences between antidepressants and placebo in
randomised trials. The psychoactive eﬀects of individual
antidepressants vary in strength and character, depending
on chemical class and composition. Tricyclic drugs are
strongly sedating and impair psychological test perform-
ance.17 SSRIs have weaker and more subtle eﬀects, but can
induce a state of emotional numbing or restriction, lethargy,
reduced libido and sexual impairment. They also occasion-
ally produce a state of agitation and tension, especially in
young people.18 Antidepressant-induced emotional numb-
ness may directly reduce the intensity of people’s feelings,
but mental and physical alterations may also produce an
ampliﬁed placebo eﬀect, by revealing to people participating
in randomised trials that they are taking an active drug. The
fact that drug/placebo diﬀerences are so small, however, sug-
gests that antidepressant-induced alterations are not clinic-
ally useful, whether they act through pharmacological or
psychological means.
Adverse eﬀects
By emphasising that psychiatric drugs change the normal
state of the brain and body, the drug-centred model high-
lights the likelihood of adverse eﬀects. Although modern
antidepressants are usually well-tolerated, there is mounting
evidence of less common but serious eﬀects, including
increased suicidal thoughts,19 fetal malformations,20 bleed-
ing, a prolonged and severe withdrawal syndrome,21 and per-
sistent sexual dysfunction after discontinuation.22 The
widespread use of antidepressants may also produce nocebo
eﬀects by undermining people’s sense of self-eﬃcacy, poten-
tially setting them up for a lifetime of chronicity and
dependence on services.
Conclusions
The public have been led to believe that depression is caused
by a chemical imbalance that antidepressants help to rectify;
however, there is no current evidence that any sort of drug
speciﬁcally targets an underlying biological abnormality,
and whether there is an underlying brain state or states spe-
ciﬁc to the experience of depression has not been demon-
strated. Ampliﬁed placebo eﬀects and the subtle emotional
alterations produced by antidepressants may account for
the small diﬀerences between antidepressants and placebo
found in some randomised controlled trials, but these
small diﬀerences are unlikely to translate into a clinically
meaningful eﬀect. Doctors need to share this evidence with
patients who are considering taking an antidepressant.
Doctors should also help people to consider the pros and
cons of using a mind-altering drug, such as an antidepres-
sant, in relation to each individual’s particular situation.
This should include discussion of alternative ways of achiev-
ing desired outcomes, using strategies that do not carry the
inherent risks of drug treatment.
Although the discovery of a speciﬁc antidepressant agent
in the future cannot be ruled out, it is possible that we mis-
understand the nature of depression, and that regarding it as
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a discrete and universal disorder may have raised false hopes
about the chance of a generally applicable ‘cure’ or treat-
ment. The alternative view of depression as part of the spec-
trum of meaningful human responses to the world suggests
that drugs will only dull the experience. In the end, the situ-
ation that provoked the negative emotion needs to be
addressed. Depression is a signal that change is needed in
some aspect of life.
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